Immuno-Oncology | Specialty

Practical Considerations With Nintedanib in Lung Adenocarcinoma

October 31st 2016

Practical Implications of the LUME-Lung 1 Findings

October 31st 2016

Lung Adenocarcinoma: Patient Selection With Ramucirumab vs Nintedanib

October 31st 2016

Differentiating Among Anti-VEGF Therapies in Lung Adenocarcinoma

October 31st 2016

Non-Driver NSCLC: Clinical Decisions in Rapidly Progressing Disease

October 31st 2016

PD-L1 Status in Second-Line Lung Adenocarcinoma

October 31st 2016

Options in Second-Line Non-Squamous NSCLC

October 31st 2016

Potential Upfront and Maintenance Strategies in NSCLC

October 31st 2016

Non-Driver Mutation Non-Squamous NSCLC

October 31st 2016

First-Line Chemotherapy Options in Lung Adenocarcinoma

October 31st 2016

James Allison Says Rational Combinations Key to Immunotherapy Success in "Cold" Tumors

October 31st 2016

Immunotherapy has been a game changer in oncology, improving survival and providing long, durable responses in melanoma, lung, head and neck cancer, and others.

EMA Accepts Avelumab Application for Merkel Cell Carcinoma

October 31st 2016

The European Medicines Agency has accepted and validated a marketing authorization application for avelumab as a treatment for patients with metastatic Merkel cell carcinoma.

CD47 Studies Take Immunotherapy in New Direction

October 31st 2016

During the past several decades, it has become increasingly clear that there is a complicated relationship between a tumor and the patient’s immune system. Although the genetic and epigenetic changes that fuel cancer development create foreign antigens that should trigger an immune response, one of the hallmarks of cancer is its ability to evade this immune recognition.

Dr. Suzanne L. Topalian on PD-L1 and Emerging Biomarkers for Immunotherapy

October 31st 2016

​Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discusses the role of the PD-L1 biomarker and other biomarkers on the horizon for the use in immunotherapy.

Dr. Janice Mehnert on Why it's a Challenge to Identify Biomarkers for Immunotherapy

October 29th 2016

​Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discusses challenges with identifying effective biomarkers in for immunotherapy agents.

Dr. O'Reilly on Resistance to Immunotherapy in Pancreatic Cancer

October 29th 2016

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses resistance to immunotherapy in patients with pancreatic cancer.

Dr. Postow on Advancements of Immunotherapy in Melanoma

October 28th 2016

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements seen with immunotherapy in the treatment of patients with melanoma.

Nivolumab Combos Explored in First-Line NSCLC Trial

October 28th 2016

Although nivolumab has demonstrated a clear survival advantage compared with chemotherapy in patients with progressive non–small cell lung cancer who express PD-L1 in their tumor cells, the same cannot be said for those who are PD-L1–negative.

Dr. Mark G. Kris on Side Effects Management with Immunotherapies

October 28th 2016

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses considerations for the management of immunotherapy toxicities.

Dr. Saenger on the Importance of Biomarkers When Administering Immunotherapy

October 27th 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses the importance of developing accurate biomarkers when it comes to administering immunotherapy.